This inventor holds 1 USPTO granted patent. Top assignee: Scripps Research Institute. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Matthew Macauley: Inventor in Immune-Targeted Therapeutics.
Introduction
Matthew Macauley is an inventor associated with Edmonton, Canada, and the Scripps Research Institute. His work includes an invention involving antibody conjugates designed to help regulate immune responses.
Latest Patents
The supplied information lists one patent associated with Macauley: Immune Cell Receptor Antibodies Conjugated to High Affinity Siglec-Ligands. The patent describes Siglec ligand-antibody conjugates and compositions intended to suppress unwanted immune responses, including allergies and anaphylaxis. The record lists 1 patent.
Career Highlights
Macauley’s listed work connects antibody-based approaches with Siglec ligands, which are presented as a means of suppressing unwanted immune activity. The supplied information identifies the Scripps Research Institute as his workplace.
Collaborations
The supplied information names James C. Paulson and Maidul Islam as Macauley’s coworkers. Their names are associated with the collaborative research context of the listed invention.
Conclusion
Matthew Macauley’s listed patent reflects research into antibody conjugates designed to suppress unwanted immune responses, including allergies and anaphylaxis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile